ACPU
KLDO

Arrowgrass Capital Partners (US)’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-45,300
Closed -$525K – 312
2019
Q2 		$525K Sell
45,300
-4,700
-9% -$68.5K 0.01% 320
2019
Q1 		$725K Buy
+50,000
New +$688K 0.02% 304

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s KLDO Position: Q3 2019 in Review

Arrowgrass Capital Partners (US) sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q3 2019, closing a stake of 45,300 shares — an estimated $525K sold.

Arrowgrass Capital Partners (US) first reported a position in KLDO in Q1 2019 and held it in 2 quarters. The position peaked at $725K in Q1 2019. 41 funds tracked by Wall St. Rank hold KLDO as of Q3 2019.

  • Arrowgrass Capital Partners (US) reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 45,300 Kaleido Biosciences, Inc. Common Stock shares in Q3 2019, an estimated $525K.
  • Arrowgrass Capital Partners (US) first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2019 and held it in 2 quarters.
  • Arrowgrass Capital Partners (US)'s Kaleido Biosciences, Inc. Common Stock position peaked at $725K in Q1 2019.
  • 41 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q3 2019.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q3 2019, filed 14 Nov 2019.